News

DENVER, Colo. – If cancer patients are to receive optimal treatment, clinicians must have an accurate histologic classification of the tumor and know its genetic characteristics, said William D. Travis, M.D., attending thoracic pathologist, Department of Pathology, at Memorial Sloan Kettering Cancer Center in New York City. Dr. Travis made his remarks today at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

DENVER, Colo. – The publication of the Eighth Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer will provide physicians around the world access to new data to more precisely stage and treat cases of lung cancer. That data, collected by the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee and presented at the 16th World Conference on Lung Cancer (WCLC) in Denver on Tuesday, Sept. 8, 2015 at the Colorado Convention Center, will be published in 2016.

DENVER, Colo. — “Despite tremendous advances in treating lung cancer, there is still no specific, diagnostic approach available to treat women,” said Dr. Silvia Novello, Associate Professor, Department of Oncology, University of Turin-Italy. Dr. Novello made her remarks while opening the press briefing today at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC), which covered many topics including a new edition of the TNM Staging System, the new WHO Classification on Tumors of the Lung and increases in the number of lung cancer in patients who never smoked.

The International Association for the Study of Lung Cancer (IASLC) will hold a press conference on Wednesday, Sept. 9, 2015 at 9:45 a.m. MDT to reveal findings from key abstracts detailing advances in lung cancer study and research. Full presentations of these abstracts and other lung cancer study advancements will take place throughout the 16th World Conference on Lung Cancer (WCLC).

The International Association for the Study of Lung Cancer (IASLC) will hold a press conference on Tuesday, Sept. 8, 2015 at 9:45 a.m. MDT to reveal findings from key abstracts detailing advances in lung cancer study and research. Full presentations of these abstracts and other lung cancer study advancements will take place throughout the 16th World Conference on Lung Cancer (WCLC).

DENVER, Colo. — Adding the angiogenesis inhibitor bevacizumab to standard treatment for malignant pleural mesothelioma (MPM) increases life expectancy without severe toxicity, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). The French multicenter randomized phase 3 trial data was presented by Dr. Arnaud Scherpereel, Head of the Pulmonary and Thoracic Oncology Department and Professor at the University Hospital (CHU) of Lille, France.

Pages